Risk of long-term complications after TFG-β1-guided very-high-dose thoracic radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 4, 2003, Pages 988-995

  Anscher, Mitchell S ^a   Marks, Lawrence B ^a   Shafman, Timothy D ^a   Clough, Robert ^a   Huang, Hong ^a   Tisch, Andrea ^a   Munley, Michael ^a   Herndon II, James E ^a   Garst, Jennifer ^a   Crawford, Jeffrey ^a   Jirtle, Randy L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dose escalation; Late complications; Lung cancer; Transforming growth factor

Indexed keywords

PATIENT TREATMENT; RADIOTHERAPY; RISK ASSESSMENT; TOXICITY;

THORACIC RADIOTHERAPY (RT);

TUMORS;

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; NEUROTOXICITY; PRIORITY JOURNAL; RADIATION DOSE; SKIN TOXICITY;

EID: 0038048219     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00184-6     Document Type: Article

References (38)

1. Graham M., Purdy J., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45:1999;323-329.
2. Fu X., Huang H., Bentel G., et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys. 50:2001;899-908.
3. Chen Y., Rubin P., Williams J., et al. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 49:2001;641-648.
4. Anscher M.S., Marks L.B., Shafman T.D., et al. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol. 19:2001;3758-3765.
5. Fan M., Marks L.B., Hollis D., et al. Can we predict radiation-induced changes in pulmonary function based on the sum of predicted regional dysfunction? J Clin Oncol. 19:2001;543-550.
6. Maguire P.D., Marks L.B., Sibley G.S., et al. 73.6 Gy and beyond: Hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. J Clin Oncol. 19:2001;705-711.
7. Anscher M.S., Kong F.M., Andrews K., et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 41:1998;1029-1035.
8. Manual for staging of cancer. 4th ed:1992;JB Lippincott, Philadelphia.
9. King S.C., Acker J.A., Kussin P.S., et al. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer Unusual toxicity and promising early results . Int J Radiat Oncol Biol Phys. 36:1996;593-599.
10. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21:1991;109-122.
11. Simon R. Clinical trials in cancer Design and analysis of clinical trials . Devita V., Hellman S., Rosenberg S. Cancer: Principles and practice of oncology. 6 ed:2001;521-538 Lippincott Williams & Wilkins, Philadelphia.
12. Kaplan E.L., Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
13. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in Stage III NSCLC. N Engl J Med. 323:1990;940-945.
14. LeChevalier T., Arriagada R., Tarayre M., et al. Significant effect of adjuvant chemotherapy on survival and locally advanced non-small cell lung cancer. J Natl Cancer Inst. 84:1992;58.
15. Schaake-Koning C., Van Den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy in inoperable non-small cell lung cancer. N Engl J Med. 326:1992;524-530.
16. Marino P., Preatoni A., Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIA and IIIB non-small cell lung cancer. Cancer. 76:1995;593-601.
17. Pritchard R., Anthony S. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer A meta-analysis . Ann Intern Med. 125:1996;723-729.
18. Perez C.A., Stanley K., Rubin P., et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung. Cancer. 45:1980;2744-2753.
19. Chemotherapy in non-small cell lung cancer A meta-analysis using updated data on individual patients from 52 randomized clinical trials . BMJ. 311:1995;899-909.
20. Perez C.A., Bauer M., Edelstein S., et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 12:1986;539-547.
21. Saunders M.I., Barltrop M.A., Rassa P., et al. The relationship between tumor response and survival following radiotherapy for carcinoma of the bronchus. Int J Radiat Oncol Biol Phys. 10:1984;503-508.
22. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with ≥69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small cell lung carcinoma Report of Radiation Therapy Oncology Group 83-11 . J Clin Oncol. 8:1990;1543-1555.
23. Dosoretz D.E., Galmarini D., Rubenstein J.H., et al. Local control in medically inoperable lung cancer An analysis of its importance in outcome and factors determining the probability of tumor eradication . Int J Radiat Oncol Biol Phys. 27:1993;507-516.
24. Stuschke M., Thames H.D. Hyperfractionated radiotherapy of human tumors Overview of the randomized clinical trials . Int J Radiat Oncol Biol Phys. 37:1997;259-267.
25. Hill R.P., Rodemann H.P., Hendry J.H., et al. Normal tissue radiobiology From the laboratory to the clinic . Int J Radiat Oncol Biol Phys. 49:2001;353-365.
26. Denham J.W., Hauer-Jensen M. The radiotherapeutic injury - A complex "wound" Radiother Oncol. 63:2002;129-145.
27. Rosenman J., Halle J., Socinski M., et al. High-dose conformal radiotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer Technical issues and results of a phase I/II trial . Int J Radiat Oncol Biol Phys. 54:2002;348-356.
28. Martin M., Lefaix J.-L., Delanian S. TGF-β1 and radiation fibrosis A master switch and a specific target? Int J Radiat Oncol Biol Phys. 47:2000;277-290.
29. Vujaskovic Z., Groen H. TGFβ, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol. 76:2000;511-516.
30. Hayman J., Martel M., Ten Haken R., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy Update of a phase I trial . J Clin Oncol. 19:2001;127-136.
31. Yorke E., Jackson A., Rosenzweig K., et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 54:2002;329-339.
32. Lind P., Marks L., Hollis D., et al. Receiver operating characteristic curve to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Biol Oncol Phys. 54:2002;340-347.
33. Zhou S.M., Marks L.B., Tracton G.S., et al. A new three-dimensional dose distribution reduction scheme for tubular organs. Med Phys. 27:2000;1727-1731.
34. Maguire P.D., Sibley G.S., Zhou S.M., et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 45:1999;97-103.
35. Bradley J., Deasy J., Bentzen S., et al. Irradiated esophageal surface area predicts for esophagitis in patients treated for non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 54:2002;105-106.
36. Kang S., Rabbani Z., Folz R., et al. Overexpression of extracellular superoxide dismutase protects mice from radiation induced lung injury. Int J Radiat Oncol Biol Phys. 54:2002;78.
37. Li Y.-Q., Ballinger J., Nordal R., et al. Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res. 61:2001;3348-3354.
38. Vujaskovic Z., Anscher M., Feng Q.-F., et al. Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys. 50:2001;851-855.